Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Lung Cancer

  Free Subscription


Articles published in J Thorac Oncol

Retrieve available abstracts of 406 articles:
HTML format



Single Articles


    December 2022
  1. DEB D, Moore AC, Basu Roy U
    In Response: Letter Received From Dr. Tadashi Nishimura Titled "What About Palliative and Supportive Care Landscapes?".
    J Thorac Oncol. 2022;17:e95-e96.
    PubMed    


  2. NISHIMURA T
    What About Palliative and Supportive Care Landscapes?
    J Thorac Oncol. 2022;17:e95.
    PubMed    


  3. GROSSO F, Cerbone L, Pasello G
    Pericardial Mesothelioma, a Disease for Brave Hearts.
    J Thorac Oncol. 2022;17:1333-1334.
    PubMed    


  4. BOGART JA
    Immune Checkpoint Inhibition for Locally Advanced NSCLC: Time to Ask New Questions?
    J Thorac Oncol. 2022;17:1330-1332.
    PubMed    


  5. OFFIN M, De Silva DL, Sauter JL, Egger JV, et al
    Multimodality Therapy in Patients With Primary Pericardial Mesothelioma.
    J Thorac Oncol. 2022;17:1428-1432.
    PubMed     Abstract available


  6. LIN EP, Hsu CY, Chiou JF, Berry L, et al
    Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit.
    J Thorac Oncol. 2022;17:1365-1374.
    PubMed     Abstract available


  7. GARASSINO MC, Mazieres J, Reck M, Chouaid C, et al
    Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.
    J Thorac Oncol. 2022;17:1415-1427.
    PubMed     Abstract available


    November 2022
  8. FOUSEK K, Horn LA, Qin H, Dahut M, et al
    An IL-15 superagonist enables anti-tumor efficacy of NK cells against all molecular variants of small cell lung cancer (SCLC).
    J Thorac Oncol. 2022 Nov 18:S1556-0864(22)01910.
    PubMed     Abstract available


  9. GARCIA-PARDO M, Chang A, Schmid S, Dong M, et al
    Respiratory and cardiometabolic comorbidities and Stage I-III non-small cell lung cancer (NSCLC) survival: A pooled analysis from the International Lung Cancer Consortium (ILCCO).
    J Thorac Oncol. 2022 Nov 14. pii: S1556-0864(22)01903.
    PubMed     Abstract available


  10. GAO S, Jin L, Meadows HW, Shafman T, et al
    Prediction of distant metastases after stereotactic body radiation therapy for early stage non-small cell lung cancer: development and external validation of a multi-institutional model.
    J Thorac Oncol. 2022 Nov 14. pii: S1556-0864(22)01909.
    PubMed     Abstract available


  11. MITSUDOMI T, Tan D, Yang JC, Ahn MJ, et al
    Expert consensus recommendations on biomarker testing in metastatic and non-metastatic non-small cell lung cancer in Asia.
    J Thorac Oncol. 2022 Nov 12. pii: S1556-0864(22)01905.
    PubMed     Abstract available


    October 2022
  12. WANG Q, Gumus ZH, Colarossi C, Memeo L, et al
    Small Cell Lung Cancer: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening and Early Detection.
    J Thorac Oncol. 2022 Oct 12. pii: S1556-0864(22)01851.
    PubMed     Abstract available


  13. PAIK PK, Fan PD, Qeriqi B, Namakydoust A, et al
    Targeting NFE2L2/KEAP1 mutations in advanced non-small cell lung cancer with the TORC1/2 inhibitor TAK-228.
    J Thorac Oncol. 2022 Oct 11. pii: S1556-0864(22)01825.
    PubMed     Abstract available


  14. HOPKINS AM, Sorich MJ
    Response to Mazzaschi and Buti.
    J Thorac Oncol. 2022;17:e90.
    PubMed    


  15. MAZZASCHI G, Buti S
    What Is the Real Impact of Concomitant Antibiotics or Proton Pump Inhibitors on Efficacy of Atezolizumab-Based Regimens in Patients With NSCLC?
    J Thorac Oncol. 2022;17:e89-e90.
    PubMed    


  16. SUMI T, Michimata H, Nagayama D, Koshino Y, et al
    Tumor-Associated Raynaud's Phenomenon Exacerbated by Administration of Immune Checkpoint Inhibitors.
    J Thorac Oncol. 2022;17:1233-1234.
    PubMed    


  17. FENG J, Leighl NB
    There Is an Unmet Need for Another Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Inhibitor.
    J Thorac Oncol. 2022;17:1175-1177.
    PubMed    


  18. DAGOGO-JACK I, Piotrowska Z
    There Is No Unmet Need for Another Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Inhibitor for Metastatic NSCLC.
    J Thorac Oncol. 2022;17:1171-1174.
    PubMed    


  19. CANGIR AK, Yumuk PF, Sak SD, Akyurek S, et al
    Lung Cancer in Turkey.
    J Thorac Oncol. 2022;17:1158-1170.
    PubMed    


  20. MOUNTZIOS G, Aggarwal C
    Pembrolizumab Administration Frequency, Dose Exposure, and Toxicity: Is Switching Safe?
    J Thorac Oncol. 2022;17:1155-1157.
    PubMed    


  21. LAU SCM, Ou SI
    And Still They Come Over Troubled Waters: Can Asia's Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC.
    J Thorac Oncol. 2022;17:1144-1154.
    PubMed    


    September 2022
  22. SMELTZER MP, Liao W, Faris NR, Fehnel C, et al
    Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening.
    J Thorac Oncol. 2022 Sep 30. pii: S1556-0864(22)01820.
    PubMed     Abstract available


  23. ZHOU C, Huang D, Fan Y, Yu X, et al
    Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial.
    J Thorac Oncol. 2022 Sep 29. pii: S1556-0864(22)01803.
    PubMed     Abstract available


  24. MINO-KENUDSON M, Schalper K, Cooper W, Dacic S, et al
    Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the IASLC Pathology Committee.
    J Thorac Oncol. 2022 Sep 29. pii: S1556-0864(22)01695.
    PubMed     Abstract available


  25. CRADDOCK M, Nestle U, Koenig J, Schimek-Jasch T, et al
    Cardiac function modifies the impact of heart base dose on survival: A voxel-wise analysis of lung cancer patients from the PET-Plan trial.
    J Thorac Oncol. 2022 Sep 18. pii: S1556-0864(22)01590.
    PubMed    


  26. IGNATIUS OU SH, Nishio M, Ahn MJ, Mok T, et al
    Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study.
    J Thorac Oncol. 2022 Sep 9. pii: S1556-0864(22)01584.
    PubMed     Abstract available


  27. IGNATIUS OU SH
    In Response to Continuation of Lorlatinib Beyond Progressive Disease.
    J Thorac Oncol. 2022;17:e86-e88.
    PubMed    


  28. ZHAO B, Ma W
    Continuation of Lorlatinib May Bring Benefits to ALK-Positive NSCLC Beyond Progressive Disease; More Things Should Be Considered.
    J Thorac Oncol. 2022;17:e85-e86.
    PubMed    


  29. BOZINOVSKI S
    Response to "Non-Tumor Cells in Tumor Specimens Impair the Accuracy of qPCR in the Detection of PD-L1 CNV and mRNA Expression".
    J Thorac Oncol. 2022;17:e84-e85.
    PubMed    


  30. ZHANG H, Chen Z, Li M, Sui Q, et al
    Nontumor cells in Tumor Specimens Impair the Accuracy of Quantitative Polymerase Chain Reaction in the Detection of Programmed Death-Ligand 1 Copy Number Variant and mRNA Expression.
    J Thorac Oncol. 2022;17:e83-e84.
    PubMed    


  31. NICHOLSON AG, Scagliotti G, Tsao MS, Yatabe Y, et al
    2021 WHO Classification of Lung Cancer: A Globally Applicable and Molecular Biomarker-Relevant Classification.
    J Thorac Oncol. 2022;17:e80-e83.
    PubMed    


  32. JAVEY M, Yaung SJ
    Incorporating Genetic Biomarkers in WHO Classification of Lung Cancer.
    J Thorac Oncol. 2022;17:e79-e80.
    PubMed    


  33. ZHAO B, Xing H, Ma W
    Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Nonsquamous NSCLC Harboring EGFR Mutations.
    J Thorac Oncol. 2022;17:e76-e77.
    PubMed    


  34. LEE J, Hong YS, Cho J, Lee J, et al
    Comment on "Is It Time for a Specific Nodal Assessment for Every NSCLC Stage?"
    J Thorac Oncol. 2022;17:e74-e75.
    PubMed    


  35. CHIAPPETTA M, Sassorossi C, Tabacco D, Lococo F, et al
    Is It Time for a Specific Nodal Assessment for Every NSCLC Stage?
    J Thorac Oncol. 2022;17:e73-e74.
    PubMed    


  36. LEE J, Ahn MJ
    A Response to the Letter to the Editor: "Bevacizumab Plus Atezolizumab in Pretreated Progressive and Metastatic Non-Small Cell Lung Cancer".
    J Thorac Oncol. 2022;17:e72-e73.
    PubMed    


  37. ZHAO B, Li H, Ma W
    Bevacizumab Plus Atezolizumab in Pretreated Progressive and Metastatic NSCLC.
    J Thorac Oncol. 2022;17:e71-e72.
    PubMed    


  38. NIYIBIZI BA, Muhizi E, Ndoli DA, Rukundo I, et al
    Lung Cancer in Rwanda.
    J Thorac Oncol. 2022;17:1074-1077.
    PubMed    


  39. MATSUOKA R, Kawai H, Ito T, Matsubara D, et al
    Determining Whether YAP1 and POU2F3 Are Antineuroendocrine Factors.
    J Thorac Oncol. 2022;17:1070-1073.
    PubMed    


  40. GIRARD N
    EGFR Tyrosine Kinase Inhibitor Sequencing Revisited: From the Revival of Old Tools to the Integration of New Agents.
    J Thorac Oncol. 2022;17:1067-1069.
    PubMed    


  41. WU TC, Lin CC
    Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2022;17:1063-1066.
    PubMed    


  42. KALCHIEM-DEKEL O, Falcon CJ, Bestvina CM, Liu D, et al
    Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.
    J Thorac Oncol. 2022;17:1130-1136.
    PubMed     Abstract available


  43. BAINE MK, Febres-Aldana CA, Chang JC, Jungbluth AA, et al
    POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC.
    J Thorac Oncol. 2022;17:1109-1121.
    PubMed     Abstract available


    August 2022
  44. PAZ-ARES LG, Ciuleanu T, Pluzanski A, Lee JS, et al
    Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
    J Thorac Oncol. 2022 Aug 29. pii: S1556-0864(22)01556.
    PubMed     Abstract available


  45. HEIDEN BT, Eaton DB Jr, Chang SH, Yan Y, et al
    Assessment of Updated Commission on Cancer Guidelines for Intraoperative Lymph Node Sampling in Early-stage Non-small Cell Lung Cancer.
    J Thorac Oncol. 2022 Aug 29. pii: S1556-0864(22)01551.
    PubMed     Abstract available


  46. VACHANI A, Carroll NM, Simoff MJ, Neslund-Dudas C, et al
    Stage Migration and Lung Cancer Incidence After Initiation of Low-Dose CT Screening.
    J Thorac Oncol. 2022 Aug 29. pii: S1556-0864(22)01553.
    PubMed     Abstract available


  47. REDIN E, Garrido-Martin EM, Valencia K, Redrado M, et al
    YES1 is a druggable oncogenic target in Small Cell Lung Cancer.
    J Thorac Oncol. 2022 Aug 18. pii: S1556-0864(22)01530.
    PubMed     Abstract available


  48. SHI Y, Chen G, Wang X, Liu Y, et al
    Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR mutated non-small cell lung cancer: results from the FURLONG study.
    J Thorac Oncol. 2022 Aug 3. pii: S1556-0864(22)01496.
    PubMed     Abstract available


  49. SMELTZER MP, Ray MA, Faris NR, Osarogiagbon RU, et al
    Genie Out of the Bottle: Is There a Role for Gene-Gene Interactions in Early Detection of Lung Cancer?
    J Thorac Oncol. 2022;17:946-948.
    PubMed    


  50. ROE OD, Creaney J
    Response to "Revisiting 'BAP1ness' in Malignant Pleural Mesothelioma".
    J Thorac Oncol. 2022;17:e69-e70.
    PubMed    


  51. YANG H, Yao F, Peng RW
    Revisiting "BAP1ness" in Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2022;17:e67-e69.
    PubMed    


  52. YANG H, Gaudino G, Bardelli F, Carbone M, et al
    Does the Amount of Asbestos Exposure Influence Prognosis?
    J Thorac Oncol. 2022;17:949-952.
    PubMed    


  53. SAVARI O, Chang JC, Bishop JA, Sakthivel MK, et al
    First Report of Thoracic Carcinoma With DEK::AFF2 Rearrangement: A Case Report.
    J Thorac Oncol. 2022;17:1050-1053.
    PubMed     Abstract available


  54. BARBIERI PG, Consonni D, Somigliana A
    Asbestos Lung Burden Does Not Predict Survival in Malignant Pleural Mesothelioma: A Necropsy-Based Study of 185 Cases.
    J Thorac Oncol. 2022;17:1042-1049.
    PubMed     Abstract available


  55. BUCKNELL NW, Belderbos J, Palma DA, Iyengar P, et al
    Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective.
    J Thorac Oncol. 2022;17:961-973.
    PubMed     Abstract available


  56. LAAKSONEN S, Kettunen E, Sutinen E, Ilonen I, et al
    Pulmonary Asbestos Fiber Burden Is Related to Patient Survival in Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2022;17:1032-1041.
    PubMed     Abstract available


    July 2022
  57. PASTORINO U, Ladisa V, Trussardo S, Sabia F, et al
    Cytisine therapy improved smoking cessation in the randomized SMILE lung cancer screening trial.
    J Thorac Oncol. 2022 Jul 21. pii: S1556-0864(22)00346.
    PubMed     Abstract available


  58. XIONG A, Ren S, Liu H, Miao L, et al
    Efficacy and safety of SH-1028 in patients with EGFR T790M positive non-small-cell lung cancer: a multicenter, single-arm, open-label, phase 2 trial.
    J Thorac Oncol. 2022 Jul 4. pii: S1556-0864(22)00327.
    PubMed     Abstract available


  59. VOTH PARK J, Chandra R, Cai L, Ganguly D, et al
    Tumor cells modulate macrophage phenotype in a novel in vitro co-culture model of the non-small cell lung cancer tumor microenvironment.
    J Thorac Oncol. 2022 Jul 4. pii: S1556-0864(22)00315.
    PubMed     Abstract available


  60. CAVIC M, Kovacevic T, Zaric B, Stojiljkovic D, et al
    Lung Cancer in Serbia.
    J Thorac Oncol. 2022;17:867-872.
    PubMed    


  61. NIHO S
    Impact of Adding Vascular Endothelial Growth Factor Inhibitor to Immune Checkpoint Inhibitor Therapy.
    J Thorac Oncol. 2022;17:865-866.
    PubMed    


  62. GHAFOOR A, Hassan R
    Somatic BAP1 Loss as a Predictive Biomarker of Overall Survival in Patients With Malignant Pleural Mesothelioma Treated With Chemotherapy.
    J Thorac Oncol. 2022;17:862-864.
    PubMed    


  63. LOUW A, Panou V, Szejniuk WM, Meristoudis C, et al
    BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.
    J Thorac Oncol. 2022;17:921-930.
    PubMed     Abstract available


  64. CARBONE M, Pass HI, Ak G, Alexander HR Jr, et al
    Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.
    J Thorac Oncol. 2022;17:873-889.
    PubMed     Abstract available


  65. HIGASHIYAMA RI, Yoshida T, Yagishita S, Ohuchi M, et al
    Safety implications of switching pembrolizumab dosage from 200 mg Q3W to 400 mg Q6W in patients with advanced non-small-cell lung cancer.
    J Thorac Oncol. 2022 Jul 1. pii: S1556-0864(22)00314.
    PubMed     Abstract available


    June 2022
  66. FERNANDEZ AI, Gavrielatou N, McCann L, Shafi S, et al
    PD-L1 and PD-L2 mRNA measured using closed system qRT-PCR are associated with outcome and high negative predictive value in immunotherapy-treated non-small cell lung cancer.
    J Thorac Oncol. 2022 Jun 25. pii: S1556-0864(22)00311.
    PubMed     Abstract available


  67. RECK M, Mok TSK, Mansfield A, De Boer R, et al
    Brief Report: Exploratory analysis of maintenance therapy in patients with extensive-stage small cell lung cancer treated first-line with atezolizumab plus carboplatin and etoposide.
    J Thorac Oncol. 2022 Jun 25. pii: S1556-0864(22)00300.
    PubMed     Abstract available


  68. HIBINO M, Uryu K, Takeda T, Kunimatsu Y, et al
    Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan.
    J Thorac Oncol. 2022 Jun 22. pii: S1556-0864(22)00295.
    PubMed     Abstract available


  69. LU S, Zhang Y, Zhang G, Zhou J, et al
    Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M mutated non-small cell lung cancer that had progressed after prior EGFR TKI therapy: A phase 2, multicenter, single-arm, open-label study.
    J Thorac Oncol. 2022 Jun 17. pii: S1556-0864(22)00297.
    PubMed     Abstract available


  70. CARDONA AF, Mejia SA, Viola L, Chamorro DF, et al
    Lung Cancer in Colombia.
    J Thorac Oncol. 2022 Jun 15. pii: S1556-0864(22)00217.
    PubMed    


  71. NGUYEN EM, Taniguchi H, Chan JM, Zhan YA, et al
    Targeting LSD1 rescues MHC class I antigen presentation and overcomes PD-L1 blockade resistance in small cell lung cancer.
    J Thorac Oncol. 2022 Jun 9. pii: S1556-0864(22)00273.
    PubMed     Abstract available


  72. RICCIUTI B, Awad MM
    Reply to Kus and Aktas.
    J Thorac Oncol. 2022;17:e64-e65.
    PubMed    


  73. KUS T, Aktas G
    Letter to the Editor Concerning Diminished Efficacy of Programmed Death-(Ligand) 1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
    J Thorac Oncol. 2022;17:e63-e64.
    PubMed    


  74. MOK T
    In Response to Outcomes by ALK Status (Immunohistochemistry or Fluorescence In Situ Hybridization) in ALEX.
    J Thorac Oncol. 2022;17:e62-e63.
    PubMed    


  75. LI M
    Outcomes by ALK Status (Immunohistochemistry or Fluorescence In Situ Hybridization) in ALEX.
    J Thorac Oncol. 2022;17:e61-e62.
    PubMed    


  76. CANDAL-PEDREIRA C, Ruano-Ravina A, Provencio M, Fernandez-Villar A, et al
    Does the Age of Inclusion in Lung Cancer Screening Studies Overestimate the Benefits?
    J Thorac Oncol. 2022;17:e59-e61.
    PubMed    


  77. SALEH MM, Scheffler M, Merkelbach-Bruse S, Wolf J, et al
    Reply to: "Survival Analysis of TP53 Co-Mutations Should be Interpreted More Cautiously".
    J Thorac Oncol. 2022;17:e57-e59.
    PubMed    


  78. BRADA M, Forbes H, Ashley S, Fenwick J, et al
    Robust Comprehensive Dataset Provides Pause for Thought.
    J Thorac Oncol. 2022;17:e56-e57.
    PubMed    


  79. SALEM A, Franks K, Greystoke A, Hanna GG, et al
    Unaccounted Confounders Limit the Ability to Draw Conclusions From Big Data Analysis Comparing Radiotherapy Fractionation Regimens in NSCLC.
    J Thorac Oncol. 2022;17:e55-e56.
    PubMed    


  80. WRIGHT GM, Goodwin D
    Response to Letter: Beyond "Personalized" to "Tumoralized" Therapy.
    J Thorac Oncol. 2022;17:e54.
    PubMed    


  81. GOTO T
    Beyond Personalized to "Tumoralized" Therapy.
    J Thorac Oncol. 2022;17:e53-e54.
    PubMed    


  82. FROST N, Griesinger F, Hoffmann H, Langer F, et al
    Lung Cancer in Germany.
    J Thorac Oncol. 2022;17:742-750.
    PubMed    


  83. CORTELLINI A, Facchinetti F, Derosa L, Pinato DJ, et al
    Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC: The Backbone Matters.
    J Thorac Oncol. 2022;17:739-741.
    PubMed    


  84. ATAY SM, Kim AW
    Possibly Two Birds or One Squirrel.
    J Thorac Oncol. 2022;17:737-738.
    PubMed    


  85. RITTBERG R, Abraham N, Laskin J, Ho C, et al
    Hyper-Sensitive? Targeted Therapy With a Primed Immune System.
    J Thorac Oncol. 2022;17:734-736.
    PubMed    


  86. VOKES NI, Chambers E, Nguyen T, Coolidge A, et al
    Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
    J Thorac Oncol. 2022;17:779-792.
    PubMed     Abstract available


  87. RUFFINI E, Rami-Porta R, Huang J, Ahmad U, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2022;17:838-851.
    PubMed     Abstract available


  88. SHIN DW, Cho JH, Ha J, Jung KW, et al
    Trends in Incidence and Survival of Patients With Thymic Epithelial Tumor in a High-Incidence Asian Country: Analysis of the Korean Central Cancer Registry 1999 to 2017.
    J Thorac Oncol. 2022;17:827-837.
    PubMed     Abstract available


  89. SHI Y, Li B, Wu L, Pan Y, et al
    Efficacy and safety of Limertinib (ASK120067) in patients with locally advanced or metastatic EGFR T790M mutated non-small cell lung cancer: a multicenter, single-arm, phase 2b study.
    J Thorac Oncol. 2022 Jun 1. pii: S1556-0864(22)00267.
    PubMed     Abstract available


  90. PICCIRILLO MC, Bonanno L, Garassino MC, Esposito G, et al
    Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small cell lung cancer. The BEVERLY multicenter randomized phase III trial.
    J Thorac Oncol. 2022 Jun 1. pii: S1556-0864(22)00268.
    PubMed     Abstract available


    May 2022
  91. KENMOTSU H, Wakuda K, Mori K, Kato T, et al
    Randomized phase II study of osimertinib plus bevacizumab versus osimertinib for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations; WJOG9717L study.
    J Thorac Oncol. 2022 May 27. pii: S1556-0864(22)00265.
    PubMed     Abstract available


  92. ZHANG F, Guo W, Zhou B, Wang S, et al
    Research article: Three-year Follow-up of Neoadjuvant PD-1 inhibitor (Sintilimab) in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2022 May 9. pii: S1556-0864(22)00216.
    PubMed     Abstract available


  93. SHEIKH HS, Munawar K, Sheikh F, Qamar MFU, et al
    Lung Cancer in Pakistan.
    J Thorac Oncol. 2022;17:602-607.
    PubMed    


  94. POLERI C
    Sex-Based Differences in Lung Cancer: Does It Matter?
    J Thorac Oncol. 2022;17:599-601.
    PubMed    


  95. EVANS WK, Warren GW, Dresler C
    Ignoring the Obvious: Smoking Cessation Improves Survival.
    J Thorac Oncol. 2022;17:596-598.
    PubMed    


  96. WOODARD GA, Cho C, Chen L
    Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response?
    J Thorac Oncol. 2022;17:592-595.
    PubMed    


  97. ZHANG C, Wu YL, Zhong WZ
    New Normal for Lung Cancer Clinical Trials Under Coronavirus Disease 2019.
    J Thorac Oncol. 2022;17:588-591.
    PubMed    


  98. FUJIKAWA R, Muraoka Y, Kashima J, Yoshida Y, et al
    Clinicopathologic and Genotypic Features of Lung Adenocarcinoma Characterized by the International Association for the Study of Lung Cancer Grading System.
    J Thorac Oncol. 2022;17:700-707.
    PubMed     Abstract available


  99. RODEN AC, Ahmad U, Cardillo G, Girard N, et al
    Thymic Carcinomas-A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group.
    J Thorac Oncol. 2022;17:637-650.
    PubMed     Abstract available


  100. AUJLA S, Aloe C, Vannitamby A, Hendry S, et al
    Programmed Death-Ligand 1 Copy Number Loss in NSCLC Associates With Reduced Programmed Death-Ligand 1 Tumor Staining and a Cold Immunophenotype.
    J Thorac Oncol. 2022;17:675-687.
    PubMed     Abstract available


  101. SAUTER JL, Dacic S, Galateau-Salle F, Attanoos RL, et al
    The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.
    J Thorac Oncol. 2022;17:608-622.
    PubMed     Abstract available


    April 2022
  102. ZHANG R, Shen S, Wei Y, Zhu Y, et al
    A large-scale genome-wide gene-gene interaction study of lung cancer susceptibility in Europeans with a trans-ethnic validation in Asians.
    J Thorac Oncol. 2022 Apr 29. pii: S1556-0864(22)00215.
    PubMed     Abstract available


  103. MOUTAFI M, Martinez-Morilla S, Divakar P, Vathiotis I, et al
    Discovery of biomarkers of resistance to immune checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profiling.
    J Thorac Oncol. 2022 Apr 28. pii: S1556-0864(22)00212.
    PubMed     Abstract available


  104. DEB D, Moore AC, Roy UB
    2021 global lung cancer therapy landscape.
    J Thorac Oncol. 2022 Apr 27. pii: S1556-0864(22)00211.
    PubMed     Abstract available


  105. LEE J, Hong YS, Cho J, Lee J, et al
    Reclassifying the IASLC R Classification According to the Extent of Nodal Dissection for Non-Small Cell Lung Cancer: One Size Does Not Fit All.
    J Thorac Oncol. 2022 Apr 21. pii: S1556-0864(22)00195.
    PubMed     Abstract available


  106. LEE J, Koh J, Kim HK, Hong S, et al
    Bevacizumab plus atezolizumab following progression on atezolizumab monotherapy in pretreated non-small cell lung cancer patients: An open-label, two-stage, phase II trial.
    J Thorac Oncol. 2022 Apr 12. pii: S1556-0864(22)00193.
    PubMed     Abstract available


  107. ELHASSAN MMA, Mohamedani AA, Mohamed SAH, Hamdoun AOA, et al
    Lung Cancer in Sudan.
    J Thorac Oncol. 2022;17:489-498.
    PubMed    


  108. REGUART N, Reyes R
    Spotlight on Camrelizumab in Advanced Squamous Lung Cancer: Another Feather in the Cap of Chinese Checkpoint Inhibitors.
    J Thorac Oncol. 2022;17:477-480.
    PubMed    


  109. YANG SR, Rekhtman N
    Molecular Testing Identifies Ultra-Late Recurrences in Lung Carcinomas: Implications for Clinical Management.
    J Thorac Oncol. 2022;17:e50-e51.
    PubMed    


  110. GOTO T
    Genomically Metastatic, but Surgically Curable?
    J Thorac Oncol. 2022;17:e49-e50.
    PubMed    


  111. LIN Y, Fu M, Inoue K, Jeon CY, et al
    Response to Letter to the Editor.
    J Thorac Oncol. 2022;17:e47-e48.
    PubMed    


  112. TANG W, Lu L, Gu JW, Chen HL, et al
    Some Thoughts Concerning the Patient Adherence to Lung Computed Tomography Screening Reporting and Data System-Recommended Screening Intervals.
    J Thorac Oncol. 2022;17:e45-e46.
    PubMed    


  113. ROSNER S, Forde PM
    Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC.
    J Thorac Oncol. 2022;17:503-509.
    PubMed    


  114. HENDRIKS LEL, Remon J, Reck M
    Chemotherapy + PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLC.
    J Thorac Oncol. 2022;17:499-502.
    PubMed    


  115. PUTORA PM, De Ruysscher DK
    Is Hypofractionation a Good Idea in Radiotherapy for Locally Advanced NSCLC?
    J Thorac Oncol. 2022;17:487-488.
    PubMed    


  116. WANG F, Zhou Q
    The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC.
    J Thorac Oncol. 2022;17:481-486.
    PubMed    


  117. OU SI, Solomon BJ, Shaw AT, Gadgeel SM, et al
    Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.
    J Thorac Oncol. 2022;17:568-577.
    PubMed     Abstract available


  118. FOLCH EE, Bowling MR, Pritchett MA, Murgu SD, et al
    NAVIGATE 24-Month Results: Electromagnetic Navigation Bronchoscopy for Pulmonary Lesions at 37 Centers in Europe and the United States.
    J Thorac Oncol. 2022;17:519-531.
    PubMed     Abstract available


  119. MALESZEWSKI JJ, Basso C, Bois MC, Glass C, et al
    The 2021 WHO Classification of Tumors of the Heart.
    J Thorac Oncol. 2022;17:510-518.
    PubMed    


    March 2022
  120. SCALERA S, Mazzotta M, Cortile C, Krasniqi E, et al
    Concise Review: Gene of The Month KEAP1-mutant non-small cell lung cancer: the catastrophic failure of a cell-protecting hub.
    J Thorac Oncol. 2022 Mar 26. pii: S1556-0864(22)00166.
    PubMed     Abstract available


  121. JAIN D, Nambirajan A, Chen G, Geisinger K, et al
    Non-small cell lung carcinoma subtyping in conventional cytology: Results of the IASLC Cytology Working Group survey to determine specific cytomorphological criteria for adenocarcinoma and squamous cell carcinoma.
    J Thorac Oncol. 2022 Mar 21. pii: S1556-0864(22)00145.
    PubMed     Abstract available


  122. LU S, Zhou Q, Liu X, Du Y, et al
    Lorlatinib for Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer: Primary Efficacy and Safety From a Phase 2 Study in China.
    J Thorac Oncol. 2022 Mar 17. pii: S1556-0864(22)00147.
    PubMed     Abstract available


  123. DETTERBECK FC, Nishimura KK, Cilento VJ, Giuliani M, et al
    The IASLC Lung Cancer Staging Project: Methods and Guiding Principles for the Development of the 9(th) Edition TNM Classification.
    J Thorac Oncol. 2022 Mar 9. pii: S1556-0864(22)00107.
    PubMed     Abstract available


  124. SCALERA S, Mazzotta M, Cappuzzo F, Ciliberto G, et al
    KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: "Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously".
    J Thorac Oncol. 2022;17:e40-e41.
    PubMed    


  125. HORINOUCHI H, Kusumoto M, Yatabe Y, Aokage K, et al
    Lung Cancer in Japan.
    J Thorac Oncol. 2022;17:353-361.
    PubMed    


  126. TEN HAAF K
    Informing Patient Surveillance for the Growing Number of Survivors of Lung Cancer.
    J Thorac Oncol. 2022;17:345-347.
    PubMed    


  127. PELOSI G
    Labeling Lung Neuroendocrine Neoplasms for Ki-67 Antigen to Score a Bull's-Eye, Not Shoot in the Dark.
    J Thorac Oncol. 2022;17:e41-e44.
    PubMed    


  128. LE X, Heymach J
    In Response.
    J Thorac Oncol. 2022;17:e39.
    PubMed    


  129. FERRARA R, Milani M, Garassino MC, Colombo MP, et al
    Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction?
    J Thorac Oncol. 2022;17:e35-e38.
    PubMed    


  130. FAN C, Zhao Q, Teng C, Jiang Z, et al
    Response to Letter to the Editor Titled "Focusing on Intrathecal Pemetrexed for Treating Leptomeningeal Metastases from NSCLC?"
    J Thorac Oncol. 2022;17:e33-e34.
    PubMed    


  131. PAN Z
    Focusing on Intrathecal Pemetrexed for Treating Leptomeningeal Metastases From NSCLC.
    J Thorac Oncol. 2022;17:e31-e32.
    PubMed    


  132. ZHANG Y, Deng C, Zheng Q, Li Y, et al
    The Grading System of Lung Adenocarcinoma: Ever-Evolving Concepts.
    J Thorac Oncol. 2022;17:e30.
    PubMed    


  133. LI S, Deng J, She Y, Hou L, et al
    Clinical Thoughts on the Predictive Value of the Newly Proposed Grading System of Invasive Pulmonary Adenocarcinoma.
    J Thorac Oncol. 2022;17:e28-e29.
    PubMed    


  134. LIN Y, Fu M, Inoue K, Jeon CY, et al
    Response to Letter to the Editor.
    J Thorac Oncol. 2022;17:e27-e28.
    PubMed    


  135. RAJAGOPAL MS, Senthilnathan R, Km G, Ram M R, et al
    Conceptual and Statistical Interpretation of a Systematic Review and Meta-Analysis on Patient Adherence to Lung-RADS-Recommended Screening Intervals in the United States.
    J Thorac Oncol. 2022;17:e25-e27.
    PubMed    


  136. DZIADZIUSZKO R
    STK11 and KEAP1 Mutations in Lung Adenocarcinoma: Solving the Puzzle Continues.
    J Thorac Oncol. 2022;17:351-352.
    PubMed    


  137. CAMIDGE DR
    The Magic of ADAURA?
    J Thorac Oncol. 2022;17:348-350.
    PubMed    


  138. LU S, Li Z
    Rethinking the Status of Chemotherapy Combined With the Addition of Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibition and Programmed Death 1 or Programmed Death-Ligand 1 Blockade.
    J Thorac Oncol. 2022;17:341-344.
    PubMed    


  139. TSAO MS, Nicholson AG, Maleszewski JJ, Marx A, et al
    Reprint of "Introduction to 2021 WHO Classification of Thoracic Tumors".
    J Thorac Oncol. 2022;17:337-340.
    PubMed    


  140. NICHOLSON AG, Tsao MS, Beasley MB, Borczuk AC, et al
    The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015.
    J Thorac Oncol. 2022;17:362-387.
    PubMed     Abstract available


  141. LU S, Wang Q, Zhang G, Dong X, et al
    Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.
    J Thorac Oncol. 2022;17:411-422.
    PubMed     Abstract available


  142. KOSARI F, Disselhorst M, Yin J, Peikert T, et al
    Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors.
    J Thorac Oncol. 2022;17:446-454.
    PubMed     Abstract available


  143. RICCIUTI B, Arbour KC, Lin JJ, Vajdi A, et al
    Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
    J Thorac Oncol. 2022;17:399-410.
    PubMed     Abstract available


  144. WU YL, John T, Grohe C, Majem M, et al
    Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.
    J Thorac Oncol. 2022;17:423-433.
    PubMed     Abstract available


  145. OFFIN M, Yang SR, Egger J, Jayakumaran G, et al
    Molecular Characterization of Peritoneal Mesotheliomas.
    J Thorac Oncol. 2022;17:455-460.
    PubMed     Abstract available


  146. HU ZI, Miettinen M, Quezado M, Lebensohn AP, et al
    Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations.
    J Thorac Oncol. 2022;17:461-466.
    PubMed     Abstract available


    February 2022
  147. MCCOACH CE, Rolfo C, Drilon A, Lacouture M, et al
    Hypersensitivity Reactions to Selpercatinib Treatment with or Without Prior Immune Checkpoint Inhibitor Therapy in Patients with Non-Small-Cell Lung Cancer in LIBRETTO-001.
    J Thorac Oncol. 2022 Feb 17. pii: S1556-0864(22)00094.
    PubMed     Abstract available


  148. HOPKINS AM, Badaoui S, Kichenadasse G, Karapetis CS, et al
    Efficacy of atezolizumab in patients with advanced non-small cell lung cancer receiving concomitant antibiotic or proton pump inhibitor treatment: pooled analysis of five randomised control trials.: Proton pump inhibitors, antibiotics, and immunothera
    J Thorac Oncol. 2022 Feb 17. pii: S1556-0864(22)00093.
    PubMed     Abstract available


  149. SMELTZER MP, Scagliotti GV, Wakelee HA, Mitsudomi T, et al
    International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials.
    J Thorac Oncol. 2022 Feb 15. pii: S1556-0864(22)00086.
    PubMed     Abstract available


  150. AHN MJ, Cho BC, Ou X, Walding A, et al
    Brief Report: Osimertinib Plus Durvalumab in Patients with EGFR-Mutated, Advanced Non-Small Cell Lung Cancer: A Phase 1b, Open-Label, Multicenter Trial.
    J Thorac Oncol. 2022 Feb 15. pii: S1556-0864(22)00081.
    PubMed     Abstract available


  151. SHI Y, Zhao Y, Yang S, Zhou J, et al
    Safety, Efficacy and Pharmacokinetics of Rezivertinib (BPI-7711) in Advanced Non-Small Cell Lung Cancer Patients with EGFR T790M Mutation: a Phase 1 Dose-Escalation and Dose-Expansion Study.
    J Thorac Oncol. 2022 Feb 15. pii: S1556-0864(22)00084.
    PubMed     Abstract available


  152. YU XQ, Yap ML, Cheng ES, Ngo PJ, et al
    Evaluating prognostic factors for sex differences in lung cancer survival: findings from a large Australian cohort.
    J Thorac Oncol. 2022 Feb 3. pii: S1556-0864(22)00085.
    PubMed    


  153. KERPEL-FRONIUS A, Tammemagi MC, Cavic M, Huber RM, et al
    Lung Cancer Screening in Persons Who Never Smoked Has to be Evaluated-A Response to Letter to the Editor.
    J Thorac Oncol. 2022;17:e20-e21.
    PubMed    


  154. FU F, Zhang Y, He N, Chen H, et al
    Emerging High-Risk Population of Lung Cancer: To Reveal the Unrevealed.
    J Thorac Oncol. 2022;17:e18-e20.
    PubMed    


  155. NAVANI N, Baldwin DR, Edwards JG, Evison M, et al
    Lung Cancer in the United Kingdom.
    J Thorac Oncol. 2022;17:186-193.
    PubMed    


  156. DERKS JL, Dingemans AC, Speel EM
    Molecular Knowledge and Clinical Relevance - Stepping Stones in Improving Classification of Lung Neuroendocrine Neoplasms.
    J Thorac Oncol. 2022;17:e8-e10.
    PubMed    


  157. PELOSI G
    The Natural History in Lung Neuroendocrine Neoplasms: The Stone Guest Who Matters.
    J Thorac Oncol. 2022;17:e5-e8.
    PubMed    


  158. MOONEN L, Derks JL, Dingemans AC, Speel EJM, et al
    Preoperative Biopsy Diagnosis in Patients With Pulmonary Carcinoids: A Biomarker Panel Will Be Crucial to Hit a Bull's Eye.
    J Thorac Oncol. 2022;17:e21-e23.
    PubMed    


  159. LIN A, Luo P, Zhang J
    Survival Analysis of TP53 Comutations Should Be Interpreted More Cautiously.
    J Thorac Oncol. 2022;17:e14-e18.
    PubMed    


  160. THOMAS NJ, Myall NJ, Sun F, Patil T, et al
    In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"
    J Thorac Oncol. 2022;17:e12-e14.
    PubMed    


  161. NARDONE V, Correale P, Mutti L, Desideri I, et al
    Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point?
    J Thorac Oncol. 2022;17:e10-e12.
    PubMed    


  162. FAIVRE-FINN C, Edwards JG, Hatton M
    Postoperative Radiation Therapy Should Not Be Used for the Therapy of Stage III-N2 NSCLC.
    J Thorac Oncol. 2022;17:197-199.
    PubMed    


  163. LIU J, Ladbury C, Kim J, Raz D, et al
    Postoperative Radiation Therapy Should Be Used for Completely Resected Stage III-N2 NSCLC in Select Patients.
    J Thorac Oncol. 2022;17:194-196.
    PubMed    


  164. NAGASAKA M, Ou SI
    Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b+ NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy.
    J Thorac Oncol. 2022;17:182-185.
    PubMed    


  165. MUTHUSAMY B, Pennell N
    Chemoimmunotherapy for EGFR-Mutant NSCLC: Still No Clear Answer.
    J Thorac Oncol. 2022;17:179-181.
    PubMed    


  166. LIN YT, Shih JY
    Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors in NSCLC: Two Heads Are Better Than One.
    J Thorac Oncol. 2022;17:176-178.
    PubMed    


  167. LASVERGNAS J, Playe M, Saint-Val L, Brillet PY, et al
    Pitfalls in Cancer Evaluation in Case of Chronic Superior Vena Cava Obstruction: Vertebral Enhancement and Hot Quadrate Sign in the Liver.
    J Thorac Oncol. 2022;17:324-326.
    PubMed    


  168. MARX A, Chan JKC, Chalabreysse L, Dacic S, et al
    The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?
    J Thorac Oncol. 2022;17:200-213.
    PubMed     Abstract available


  169. NOGAMI N, Barlesi F, Socinski MA, Reck M, et al
    IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
    J Thorac Oncol. 2022;17:309-323.
    PubMed     Abstract available


    January 2022
  170. BRADA M, Forbes H, Ashley S, Fenwick J, et al
    Improving outcomes in non-small cell lung cancer; optimum dose fractionation in radical radiotherapy matters.
    J Thorac Oncol. 2022 Jan 26. pii: S1556-0864(22)00051.
    PubMed     Abstract available


  171. WHISENANT JG, Baena J, Cortellini A, Huang LC, et al
    A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry.
    J Thorac Oncol. 2022 Jan 24. pii: S1556-0864(22)00033.
    PubMed     Abstract available


  172. SHILPAKAR R, Paudel BD, Sharma R, Silwal SR, et al
    Lung Cancer in Nepal.
    J Thorac Oncol. 2022;17:22-29.
    PubMed    


  173. MASAGO K, Fujita S
    Effect of Coronavirus Disease 2019 Vaccine-Related Lymphadenopathy on Lung Cancer Treatment.
    J Thorac Oncol. 2022;17:16-18.
    PubMed    


  174. SALLOUM RG, Braithwaite D
    Expansion of Guideline-Recommended Lung Cancer Screening Eligibility: Implications for Health Equity of Joint Screening and Cessation Interventions.
    J Thorac Oncol. 2022;17:13-15.
    PubMed    


  175. TSAO MS, Nicholson AG, Maleszewski JJ, Marx A, et al
    Introduction to 2021 WHO Classification of Thoracic Tumors.
    J Thorac Oncol. 2022;17:e1-e4.
    PubMed    


  176. FENNELL DA, Dulloo S
    Chemotherapy With or Without Bevacizumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma.
    J Thorac Oncol. 2022;17:34-37.
    PubMed    


  177. BAAS P
    Nivolumab Plus Ipilimumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma.
    J Thorac Oncol. 2022;17:30-33.
    PubMed    


  178. JOUBERT P, Travis WD
    Prognostic Impact of Ground-Glass Opacity/Lepidic Component in Pulmonary Adenocarcinoma: A Hazy Staging Dilemma.
    J Thorac Oncol. 2022;17:19-21.
    PubMed    


  179. YAMAMOTO H, Togashi Y
    Programmed Death-Ligand 1-Rich Premetastatic Niche in Adjuvant Chemotherapy.
    J Thorac Oncol. 2022;17:10-12.
    PubMed    


  180. GROSS DJ, Chintala NK, Vaghjiani RG, Grosser R, et al
    Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma.
    J Thorac Oncol. 2022;17:89-102.
    PubMed     Abstract available


  181. OKUBO Y, Kashima J, Teishikata T, Muraoka Y, et al
    Prognostic Impact of the Histologic Lepidic Component in Pathologic Stage IA Adenocarcinoma.
    J Thorac Oncol. 2022;17:67-75.
    PubMed     Abstract available


  182. LIN Y, Fu M, Ding R, Inoue K, et al
    Patient Adherence to Lung CT Screening Reporting & Data System-Recommended Screening Intervals in the United States: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2022;17:38-55.
    PubMed     Abstract available


    December 2021
  183. CHO BC, Han JY, Kim SW, Lee KH, et al
    A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2021 Dec 24. pii: S1556-0864(21)03403.
    PubMed     Abstract available


  184. CAINI S, Del Riccio M, Vettori V, Scotti V, et al
    Quitting smoking at or around diagnosis improves the overall survival of lung cancer patients: a systematic review and meta-analysis.
    J Thorac Oncol. 2021 Dec 17. pii: S1556-0864(21)03404.
    PubMed     Abstract available


  185. REN S, Chen J, Xu X, Jiang T, et al
    Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous non-small-cell lung cancer (CameL-sq): a phase 3 trial.
    J Thorac Oncol. 2021 Dec 16. pii: S1556-0864(21)03392.
    PubMed     Abstract available


  186. EBERL M, Tanaka LF, Kraywinkel K, Klug SJ, et al
    Incidence of smoking-related second primary cancers after lung cancer in Germany: an analysis of nationwide cancer registry data.
    J Thorac Oncol. 2021 Dec 10. pii: S1556-0864(21)03390.
    PubMed     Abstract available


  187. HUBER RM, Cavic M, Kerpel-Fronius A, Viola L, et al
    Lung Cancer Screening Considerations During Respiratory Infection Outbreaks, Epidemics or Pandemics: An IASLC Early Detection and Screening Committee Report.
    J Thorac Oncol. 2021 Dec 2. pii: S1556-0864(21)03326.
    PubMed     Abstract available


  188. PARK S, Choi CM, Hwang SS, Choi YL, et al
    Lung Cancer in Korea.
    J Thorac Oncol. 2021;16:1988-1993.
    PubMed    


  189. BIAN Y, Liang J, Shan G, Zhan C, et al
    Combining Clinical and Molecular Characteristics to Precisely Predict the Prognosis of Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2021;16:e99-e100.
    PubMed    


  190. KUMAR A, Kumar S, Gilja S, Potter A, et al
    Encouraging Guideline-Concordant Treatment for T3 NSCLC.
    J Thorac Oncol. 2021;16:e98-e99.
    PubMed    


  191. LI M, Liang J, Bi G, Zhan C, et al
    Could T3Satell Tumors Be Considered Reclassified as T2b?
    J Thorac Oncol. 2021;16:e97-e98.
    PubMed    


  192. MORGENSZTERN D, Govindan R
    Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation.
    J Thorac Oncol. 2021;16:1999-2001.
    PubMed    


  193. AREDO JV, Hellyer JA, Neal JW, Wakelee HA, et al
    Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:1994-1998.
    PubMed    


  194. BELDA-SANCHIS J, Trujillo-Reyes JC, Martinez-Tellez E, Cladellas-Gutierrez E, et al
    Brain Metastasis From Thymic Epithelial Tumors: Strengthening the Evidence, a Call for Action.
    J Thorac Oncol. 2021;16:1984-1987.
    PubMed    


  195. PELOSI G
    KEAP1 and TP53 (Co)mutation in Lung Adenocarcinoma: Another Bullet for Immunotherapy?
    J Thorac Oncol. 2021;16:1979-1983.
    PubMed    


  196. BUGLIONI S, Marino M
    Pitfalls in Molecular Testing and the Added Value of the Cancer Research Biomedical Community.
    J Thorac Oncol. 2021;16:1976-1978.
    PubMed    


  197. BENITEZ JC, Boucher ME, Dansin E, Kerjouan M, et al
    Central Nervous System Metastases in Thymic Epithelial Tumors: A Brief Report of Real-World Insight From RYTHMIC.
    J Thorac Oncol. 2021;16:2144-2149.
    PubMed     Abstract available


  198. SCALERA S, Mazzotta M, Corleone G, Sperati F, et al
    KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
    J Thorac Oncol. 2021;16:2065-2077.
    PubMed     Abstract available


  199. TEISHIKATA T, Shiraishi K, Shinno Y, Kobayashi Y, et al
    An Alert to Possible False Positives With a Commercial Assay for MET Exon 14 Skipping.
    J Thorac Oncol. 2021;16:2133-2138.
    PubMed     Abstract available


  200. YANG Y, Sun J, Wang Z, Fang J, et al
    Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.
    J Thorac Oncol. 2021;16:2109-2120.
    PubMed     Abstract available


    November 2021
  201. LEIGHL NB, Laurie SA, Goss GD, Hughes BGM, et al
    CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer.
    J Thorac Oncol. 2021 Nov 17. pii: S1556-0864(21)03322.
    PubMed     Abstract available


  202. ROLFO C, Meshulami N, Russo A, Krammer F, et al
    Lung Cancer and SARS-CoV-2 infection: Identifying important knowledge gaps for investigation.
    J Thorac Oncol. 2021 Nov 10. pii: S1556-0864(21)03309.
    PubMed     Abstract available


  203. GOUNANT V, Ferre VM, Soussi G, Charpentier C, et al
    Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses.
    J Thorac Oncol. 2021 Nov 2. pii: S1556-0864(21)03286.
    PubMed     Abstract available


  204. STOCK-MARTINEAU S, Shepherd FA
    EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:1793-1797.
    PubMed    


  205. MOORE S, Wheatley-Price P
    EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:1788-1792.
    PubMed    


  206. YANG C, Li Y, Xiao SY
    Do We Really Understand the Relationship Between Expression of ACE2 and Coronavirus Disease 2019 Lung Pathophysiology?
    J Thorac Oncol. 2021;16:1785-1787.
    PubMed    


  207. LOPEZ-CASTRO R, Recondo G, Gorria T, Mezquita L, et al
    A New Pretreatment Mesothelioma Risk Score: Integrating Clinical and Molecular Factors for Predicting Outcomes in Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2021;16:1782-1784.
    PubMed    


  208. ZHU VW, Ou SI
    Ensartinib (X-396), an Approved ALK Inhibitor, Falls Out as a Clinically Relevant ROS1 Inhibitor.
    J Thorac Oncol. 2021;16:1778-1781.
    PubMed    


  209. ADJEI AA
    Tackling the High Cost of Oncology Drugs.
    J Thorac Oncol. 2021;16:1774-1777.
    PubMed    


  210. DE BAERE T, Woodrum D, Tselikas L, Abtin F, et al
    The ECLIPSE Study: Efficacy of Cryoablation on Metastatic Lung Tumors With a 5-Year Follow-Up.
    J Thorac Oncol. 2021;16:1840-1849.
    PubMed     Abstract available


  211. MIKUBO M, Inoue Y, Liu G, Tsao MS, et al
    Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy.
    J Thorac Oncol. 2021;16:1798-1809.
    PubMed     Abstract available


  212. VAN DEN BROEK MFM, Levy S, Buikhuisen WA, Dijke K, et al
    Well-Differentiated Bronchopulmonary Neuroendocrine Tumors: More Than One Entity.
    J Thorac Oncol. 2021;16:1810-1820.
    PubMed     Abstract available


  213. CHIAPPETTA M, Lococo F, Zanfrini E, Moroni R, et al
    The International Thymic Malignancy Interest Group Classification of Thymoma Recurrence: Survival Analysis and Perspectives.
    J Thorac Oncol. 2021;16:1936-1945.
    PubMed     Abstract available


  214. SAALFELD FC, Wenzel C, Christopoulos P, Merkelbach-Bruse S, et al
    Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations.
    J Thorac Oncol. 2021;16:1952-1958.
    PubMed     Abstract available


  215. YEAP BY, De Rienzo A, Gill RR, Oster ME, et al
    Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2021;16:1925-1935.
    PubMed     Abstract available


    October 2021
  216. PAZ-ARES LG, Ramalingam SS, Ciuleanu TE, Lee JS, et al
    First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
    J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03207.
    PubMed     Abstract available


  217. MEZA R, Cao P, Jeon J, Taylor KL, et al
    Brief Report: Impact of joint lung cancer screening and cessation interventions under the new USPSTF recommendations.
    J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03208.
    PubMed     Abstract available


  218. ROBBINS HA, Cheung LC, Chaturvedi AK, Baldwin DR, et al
    Management of lung cancer screening results based on individual prediction of current and future lung cancer risk.
    J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03244.
    PubMed     Abstract available


  219. HUO KG, Notsuda H, Fang Z, Liu NF, et al
    Lung cancer driven by BRAF(G469V) mutation is targetable by EGFR kinase inhibitors.
    J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03205.
    PubMed     Abstract available


  220. SONG Z, Lian S, Mak S, Chow MZ, et al
    Deep RNA sequencing revealed fusion junctional heterogeneity may predict crizotinib treatment efficacy in ALK-rearranged non-small cell lung cancer.
    J Thorac Oncol. 2021 Oct 6. pii: S1556-0864(21)03219.
    PubMed     Abstract available


  221. DZIADZIUSZKO R, Didkowska J, Jassem J
    Authors' Reply to Role of Primary Prevention in Lung Cancer Control in Poland.
    J Thorac Oncol. 2021;16:e94-e95.
    PubMed    


  222. ZATONSKI WA, Janik-Koncewicz K, Zatonski M
    Role of Primary Prevention in Lung Cancer Control in Poland.
    J Thorac Oncol. 2021;16:e93-e94.
    PubMed    


  223. OCAK S, Tournoy K, Berghmans T, Demedts I, et al
    Lung Cancer in Belgium.
    J Thorac Oncol. 2021;16:1610-1621.
    PubMed    


  224. TSIM S, Alexander L, Kelly C, Shaw A, et al
    Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases.
    J Thorac Oncol. 2021;16:1705-1717.
    PubMed     Abstract available


  225. DERKS JL, Rijnsburger N, Hermans BCM, Moonen L, et al
    Clinical-Pathologic Challenges in the Classification of Pulmonary Neuroendocrine Neoplasms and Targets on the Horizon for Future Clinical Practice.
    J Thorac Oncol. 2021;16:1632-1646.
    PubMed     Abstract available


  226. LUO J, Beattie JA, Fuentes P, Rizvi H, et al
    Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events.
    J Thorac Oncol. 2021;16:1759-1764.
    PubMed     Abstract available


  227. DENG C, Zheng Q, Zhang Y, Jin Y, et al
    Validation of the Novel International Association for the Study of Lung Cancer Grading System for Invasive Pulmonary Adenocarcinoma and Association With Common Driver Mutations.
    J Thorac Oncol. 2021;16:1684-1693.
    PubMed     Abstract available


    September 2021
  228. SALEH MM, Scheffler M, Merkelbach-Bruse S, Scheel AH, et al
    Comprehensive Analysis of TP53 and KEAP1 Mutations and their Impact on Survival in Localized and Advanced Stage Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Sep 30. pii: S1556-0864(21)03187.
    PubMed     Abstract available


  229. QU S, Fetsch P, Thomas A, Pommier Y, et al
    Molecular Subtypes of Primary Small Cell Lung Cancer Tumors and Their Associations with Neuroendocrine and Therapeutic Markers.
    J Thorac Oncol. 2021 Sep 14. pii: S1556-0864(21)03186.
    PubMed     Abstract available


  230. NISHINO M, Hatabu H, Ricciuti B, Vaz V, et al
    Brief Report Axillary lymphadenopathy after COVID-19 vaccinations in patients with thoracic malignancy: Incidence, predisposing factors, and imaging characteristics.
    J Thorac Oncol. 2021 Sep 7. pii: S1556-0864(21)03184.
    PubMed     Abstract available


  231. BESTVINA CM, Pointer KB, Karrison T, Al-Hallaq H, et al
    A Phase I Trial of Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-Small Cell Lung Cancer (COSINR Study).
    J Thorac Oncol. 2021 Sep 6. pii: S1556-0864(21)02441.
    PubMed     Abstract available


  232. TRAN HTT, Nguyen S, Nguyen KK, Pham DX, et al
    Lung Cancer in Vietnam.
    J Thorac Oncol. 2021;16:1443-1448.
    PubMed    


  233. SINGH AK, Sands JM
    Yet Another Reminder of the Value of Lung Cancer Screening.
    J Thorac Oncol. 2021;16:1437-1439.
    PubMed    


  234. ZHAO H, Zhang Z, Zhang L
    Response to: The Role of Dual Inhibition of EGFR and Vascular EGF(R) in the Treatment of NSCLC With EGFR Mutation.
    J Thorac Oncol. 2021;16:e72-e76.
    PubMed    


  235. YAMAOKA T, Kim YH, Iwatsubo S, Nishimura Y, et al
    The Role of Dual Inhibition of EGFR and Vascular Endothelial Growth Factor (Receptor) in the Treatment of NSCLC With EGFR Mutation.
    J Thorac Oncol. 2021;16:e71-e72.
    PubMed    


  236. BORZI C, Caiola E, Ganzinelli M, Centonze G, et al
    miR-17 Epigenetic Modulation of LKB1 Expression in Tumor Cells Uncovers a New Group of Patients With Poor-Prognosis NSCLC.
    J Thorac Oncol. 2021;16:e68-e70.
    PubMed    


  237. BI G, Liang J, Shan G, Zhan C, et al
    Some Thoughts Concerning the Mutational Background of Cell Lines and Heterogeneity of Bulk Tumor.
    J Thorac Oncol. 2021;16:e67-e68.
    PubMed    


  238. LEE HY
    A Wake-Up Call for Immune Checkpoint Inhibitor-Related Pneumonitis.
    J Thorac Oncol. 2021;16:1440-1442.
    PubMed    


  239. BIRONZO P, Passiglia F, Novello S
    Winds From the ORIENT: New Data to Inform RATIONAL Choice?
    J Thorac Oncol. 2021;16:1434-1436.
    PubMed    


  240. UPRETY D, Remon J, Adjei AA
    All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLC.
    J Thorac Oncol. 2021;16:1429-1433.
    PubMed    


  241. LIAO BC, Chih-Hsin Yang J
    Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:1426-1428.
    PubMed    


  242. NAKASHIMA K, Tsubata Y, Niihara H, Araki A, et al
    Palm Pustules Induced by Pemetrexed.
    J Thorac Oncol. 2021;16:1589-1591.
    PubMed    


  243. POZZESSERE C, Lazor R, Jumeau R, Peters S, et al
    Imaging Features of Pulmonary Immune-related Adverse Events.
    J Thorac Oncol. 2021;16:1449-1460.
    PubMed     Abstract available


  244. VANDENHOECK J, van Meerbeeck JP, Fransen E, Raskin J, et al
    DNA Methylation as a Diagnostic Biomarker for Malignant Mesothelioma: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2021;16:1461-1478.
    PubMed     Abstract available


    August 2021
  245. CAMIDGE DR, Kim HR, Ahn MJ, Yang JC, et al
    Brigatinib versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Inhibitor-Naive Advanced ALK-Positive Non-Small Cell Lung Cancer: Final Results of the Phase 3 ALTA-1L Trial.
    J Thorac Oncol. 2021 Aug 30. pii: S1556-0864(21)02398.
    PubMed     Abstract available


  246. DOROSHOW DB, Wei W, Gupta S, Zugazagoitia J, et al
    PD-L1 tumor proportion score and overall survival from first-line pembrolizumab in patients with nonsquamous versus squamous non-small cell lung cancer.
    J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02392.
    PubMed     Abstract available


  247. PLANCHARD D, Besse B, Groen HJM, Hashemi SMS, et al
    Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer: Updated 5-year survival rates and genomic analysis.
    J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02403.
    PubMed     Abstract available


  248. THOMAS NJ, Myall NJ, Sun F, Patil T, et al
    Brain Metastases in EGFR- and ALK-positive Non-Small Cell Lung Cancer: Outcomes of CNS Penetrant Tyrosine Kinase Inhibitors (TKIs) Alone versus in Combination with Radiation.
    J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02401.
    PubMed     Abstract available


  249. KERPEL-FRONIUS A, Tammemagi M, Cavic M, Henschke C, et al
    Screening for lung cancer in individuals who never smoked: An IASLC Early Detection and Screening Committee Report.
    J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02391.
    PubMed     Abstract available


  250. SHIRASAWA M, Yoshida T, Shimoda Y, Takayanagi D, et al
    Differential Immune-Related Microenvironment Determines PD-1/PD-L1 Blockade Efficacy in Advanced Non-Small Cell Lung Cancer Patients.
    J Thorac Oncol. 2021 Aug 19. pii: S1556-0864(21)02373.
    PubMed     Abstract available


  251. YAMAGUCHI H, Wakuda K, Fukuda M, Kenmotsu H, et al
    A phase II study of osimertinib for radiotherapy-naive CNS metastasis from non-small cell lung cancer: Results for the T790M cohort of the OCEAN study (LOGIK1603/WJOG9116L).
    J Thorac Oncol. 2021 Aug 19. pii: S1556-0864(21)02372.
    PubMed     Abstract available


  252. WALIANY S, Zhu H, Wakelee H, Padda SK, et al
    Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.
    J Thorac Oncol. 2021 Aug 18. pii: S1556-0864(21)02377.
    PubMed     Abstract available


  253. QUAIFE SL, Dickson JL, Brain KE, Kurtidu C, et al
    Psychological targets for lung cancer screening uptake: a prospective longitudinal cohort study.
    J Thorac Oncol. 2021 Aug 14. pii: S1556-0864(21)02369.
    PubMed     Abstract available


  254. HERZOG BH, Devarakonda S, Govindan R
    Overcoming chemotherapy resistance in Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Aug 3. pii: S1556-0864(21)02333.
    PubMed    


  255. AREDO JV, Wakelee HA, Han SS
    A Moving Target: Integration of Smoking Cessation Into Screening for Second Primary Lung Cancer.
    J Thorac Oncol. 2021;16:e59-e60.
    PubMed    


  256. PELOSI G, Pasini F
    Over-Time Risk of Lung Cancer Is Largely Owing to Continuing Smoking Exposition: A Good Reason to Quit.
    J Thorac Oncol. 2021;16:e57-e59.
    PubMed    


  257. SINGH N, Agrawal S, Jiwnani S, Khosla D, et al
    Lung Cancer in India.
    J Thorac Oncol. 2021;16:1250-1266.
    PubMed    


  258. BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
    Reaction on the Interpretation of the Hippocampus Avoidance Prophylactic Cranial Irradiation Trial in SCLC (NCT01780675).
    J Thorac Oncol. 2021;16:e63-e65.
    PubMed    


  259. MLADKOVA N, Lo S, Brown PD, Gondi V, et al
    Hippocampal Avoidance Prophylactic Cranial Irradiation: Interpreting the Evidence.
    J Thorac Oncol. 2021;16:e60-e63.
    PubMed    


  260. COOPER WA, Lantuejoul S, Mino-Kenudson M
    Predicting Response to Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Blockade in NSCLC-Is Multiplex Immunohistochemistry or Immunofluorescence the Answer?
    J Thorac Oncol. 2021;16:1247-1249.
    PubMed    


  261. RUIZ J, Chan M, Strowd RE
    Treatment of Leptomeningeal Metastases: New Hammer, the Same Nail.
    J Thorac Oncol. 2021;16:1244-1246.
    PubMed    


  262. SMIT EF, Belderbos J
    Concurrent Chemoradiation, Adjuvant Durvalumab, and KEAP-1/NRF-2 Mutations: A Happy Marriage?
    J Thorac Oncol. 2021;16:1242-1243.
    PubMed    


  263. COLOMBO M, Ndembe G, Broggini M
    KRAS Targeting and Resistance: Anticipating the Expectable.
    J Thorac Oncol. 2021;16:1239-1241.
    PubMed    


  264. HUDDAR P, Califano R
    Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibition as Maintenance Treatment for SCLC: The Search Must Continue.
    J Thorac Oncol. 2021;16:1236-1238.
    PubMed    


  265. SHAVERDIAN N, Offin M, Shepherd AF, Simone CB 2nd, et al
    The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors.
    J Thorac Oncol. 2021;16:1392-1402.
    PubMed     Abstract available


  266. FAN C, Zhao Q, Li L, Shen W, et al
    Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier:
    J Thorac Oncol. 2021;16:1359-1368.
    PubMed     Abstract available


  267. YEONG J, Suteja L, Simoni Y, Lau KW, et al
    Intratumoral CD39(+)CD8(+) T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC.
    J Thorac Oncol. 2021;16:1349-1358.
    PubMed     Abstract available


  268. KOGA T, Suda K, Fujino T, Ohara S, et al
    KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    J Thorac Oncol. 2021;16:1321-1332.
    PubMed     Abstract available


  269. YOTSUKURA M, Asamura H, Motoi N, Kashima J, et al
    Long-Term Prognosis of Patients With Resected Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma of the Lung.
    J Thorac Oncol. 2021;16:1312-1320.
    PubMed     Abstract available


  270. BORZI C, Ganzinelli M, Caiola E, Colombo M, et al
    LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments.
    J Thorac Oncol. 2021;16:1298-1311.
    PubMed     Abstract available


    July 2021
  271. DZIADZIUSZKO R, Mok T, Peters S, Han JY, et al
    Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic Non-Small Cell Lung Cancer: Initial Results of the Phase 2 ALK-Positive Cohort.
    J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02321.
    PubMed     Abstract available


  272. PATEL SA, Herynk MH, Cascone T, Saigal B, et al
    Estrogen promotes resistance to bevacizumab in murine models of non-small cell lung cancer.
    J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02320.
    PubMed     Abstract available


  273. SOCINSKI MA, Nishio M, Jotte RM, Cappuzzo F, et al
    IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.
    J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02322.
    PubMed     Abstract available


  274. SMELTZER MP, Lee YS, Faris NR, Fehnel C, et al
    Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected Non-small Cell Lung Cancer (NSCLC) in a High Mortality Area of the United States.
    J Thorac Oncol. 2021 Jul 16. pii: S1556-0864(21)02299.
    PubMed     Abstract available


  275. STEWART CA, Gay CM, Ramkumar K, Cargill KR, et al
    Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.
    J Thorac Oncol. 2021 Jul 15. pii: S1556-0864(21)02294.
    PubMed     Abstract available


  276. JASSEM J, de Marinis F, Giaccone G, Vergnenegre A, et al
    Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02286.
    PubMed     Abstract available


  277. AI X, Wang Q, Cheng Y, Liu X, et al
    Safety but Limited Efficacy of Ensartinib in ROS1-Positive Non-small Cell Lung Cancer: A Single-arm, Multicenter Phase II study.
    J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02290.
    PubMed     Abstract available


  278. POWELL SF, Rodriguez-Abreu D, Langer CJ, Tafreshi A, et al
    Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407.
    J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02287.
    PubMed     Abstract available


  279. MYERS R, Brauer M, Dummer T, Atkar-Khattra S, et al
    High Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers with Lung Cancer.
    J Thorac Oncol. 2021 Jul 10. pii: S1556-0864(21)02256.
    PubMed     Abstract available


  280. WANG Y, Li J, Chang S, Dong Y, et al
    Risk and influencing factors for subsequent primary lung cancer after treatment of breast cancer: a systematic review and two meta-analyses based on four million cases.
    J Thorac Oncol. 2021 Jul 10. pii: S1556-0864(21)02293.
    PubMed     Abstract available


  281. ROLFO C, Mack P, Scagliotti GV, Aggarwal C, et al
    Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC).
    J Thorac Oncol. 2021 Jul 8. pii: S1556-0864(21)02284.
    PubMed    


  282. HANN CL, Burns TF, Dowlati A, Morgensztern D, et al
    Brief Report: A Phase 1 Study Evaluating Rovalpituzumab Tesirine (Rova-T) in Frontline Treatment of Patients With Extensive-Stage Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02289.
    PubMed     Abstract available


  283. PARK HR, Kim TM, Lee Y, Kim S, et al
    Acquired resistance to third-generation EGFR tyrosine kinase inhibitors in patients with de novo EGFR(T790M)-mutant non-small cell lung cancer.
    J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02254.
    PubMed     Abstract available


  284. KUMAR A, Kumar S, Gilja S, Potter A, et al
    Reconsidering the American Joint Committee on Cancer 8(th) Edition TNM Staging Manual Classifications for T2b/T3 Non-small-cell Lung Cancer.
    J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02283.
    PubMed     Abstract available


  285. MOUNTZIOS G, Gkiozos I, Stratakos G, Pissakas G, et al
    Lung Cancer in Greece.
    J Thorac Oncol. 2021;16:1058-1066.
    PubMed    


  286. UGUEN A
    Each RET Break-Apart Fluorescence In Situ Hybridization Probe Requires Proper Interpretation Criteria.
    J Thorac Oncol. 2021;16:e55.
    PubMed    


  287. ZHU VW, Zhang SS, Zhang J, Swensen J, et al
    Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib.
    J Thorac Oncol. 2021;16:e51-e54.
    PubMed    


  288. DOWLATI A, Chan T
    Pursuing Immunotherapeutic Targets in SCLC.
    J Thorac Oncol. 2021;16:1056-1057.
    PubMed    


  289. GRANNIS FW JR
    Do Cancer Screening Researchers Have a Continuing Ethical Obligation to Their Study Subjects?
    J Thorac Oncol. 2021;16:1053-1055.
    PubMed    



  290. Dr. Gouri Shankar Bhattacharyya, MD, PhD, FRCP: In Memoriam (October 31, 1958-May 1, 2021).
    J Thorac Oncol. 2021;16:1043-1044.
    PubMed    


  291. LE-RADEMACHER J, Wang X
    Time-To-Event Data: An Overview and Analysis Considerations.
    J Thorac Oncol. 2021;16:1067-1074.
    PubMed     Abstract available


  292. GOODWIN D, Rathi V, Conron M, Wright GM, et al
    Genomic and Clinical Significance of Multiple Primary Lung Cancers as Determined by Next-Generation Sequencing.
    J Thorac Oncol. 2021;16:1166-1175.
    PubMed     Abstract available


  293. YANG SR, Chang JC, Leduc C, Tan KS, et al
    Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling.
    J Thorac Oncol. 2021;16:1188-1199.
    PubMed     Abstract available


  294. LINDBERG K, Grozman V, Karlsson K, Lindberg S, et al
    The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy.
    J Thorac Oncol. 2021;16:1200-1210.
    PubMed     Abstract available


  295. HAN DH, Duan F, Wu Y, Goo JM, et al
    Clinical Significance of Lung-RADS Category 3 Lesions in the National Lung Screening Trial.
    J Thorac Oncol. 2021;16:1118-1126.
    PubMed     Abstract available


    June 2021
  296. WARREN GW, Lim VS, Chowdhary M, Marwaha G, et al
    Brief Report: New Pulmonary Infiltrates Observed on Computed Tomography Based Image Guidance for Radiotherapy Warrant Diagnostic Workup for COVID-19.
    J Thorac Oncol. 2021 Jun 21. pii: S1556-0864(21)02232.
    PubMed     Abstract available


  297. AKAMATSU H, Murakami H, Harada H, Shimizu J, et al
    Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced non-small cell lung cancer with EGFR mutation; West Japan Oncology Group 6911L.
    J Thorac Oncol. 2021 Jun 8. pii: S1556-0864(21)02190.
    PubMed     Abstract available


  298. SU CC, Wu JT, Neal JW, Popat RA, et al
    Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis.
    J Thorac Oncol. 2021 Jun 3. pii: S1556-0864(21)02181.
    PubMed     Abstract available


  299. ANG YLE, Chia PL, Chua KLM, Devanand A, et al
    Lung Cancer in Singapore.
    J Thorac Oncol. 2021;16:906-911.
    PubMed    


  300. RAMI-PORTA R, Goldstraw P, Asamura H
    Commemorating the Silver Anniversary of the International Association for the Study of Lung Cancer International Workshop on Intrathoracic Staging.
    J Thorac Oncol. 2021;16:902-905.
    PubMed    


  301. GRASS GD, Scott JG, Sedor G, Kattan MW, et al
    Response to: Noncancer Cells in Tumor Samples May Bias the Predictive Genomically Adjusted Radiation Dose.
    J Thorac Oncol. 2021;16:e48-e49.
    PubMed    


  302. DU Y, Hu Z, Liang J, Zhan C, et al
    Noncancer Cells in Tumor Samples May Bias the Predictive Genomic-Adjusted Radiation Dose.
    J Thorac Oncol. 2021;16:e47.
    PubMed    


  303. RYAN BM
    In Response: Using Propensity Score Matching to Balance the Baseline Characteristics.
    J Thorac Oncol. 2021;16:e46.
    PubMed    


  304. LIANG J, Hu Z, Zhan C, Wang Q, et al
    Using Propensity Score Matching to Balance the Baseline Characteristics.
    J Thorac Oncol. 2021;16:e45-e46.
    PubMed    


  305. BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
    Why Did the Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC Not Reveal a Difference?
    J Thorac Oncol. 2021;16:e42-e45.
    PubMed    


  306. BREEN WG, Brown PD, Laack NN
    Hippocampal Avoidance Prophylactic Cranial Irradiation for SCLC.
    J Thorac Oncol. 2021;16:e41-e42.
    PubMed    


  307. DEUTSCH E, Cengel KA, Galluzzi L, Levy A, et al
    Could Protons Promote Tumor Control by Avoiding Lymphopenia?
    J Thorac Oncol. 2021;16:e39-e41.
    PubMed    


  308. BAUMAN J, Borghaei H
    To Give or Not to Give: Consolidative Durvalumab in EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:894-896.
    PubMed    


  309. WARREN GW, Evans WK, Dresler C
    Critical Determinants of Cancer Treatment Outcomes: Smoking Must Be Addressed at the Highest Levels in Cancer Care.
    J Thorac Oncol. 2021;16:891-893.
    PubMed    


  310. CAMIDGE DR, Otterson GA, Clark JW, Ignatius Ou SH, et al
    Crizotinib in Patients With MET-Amplified NSCLC.
    J Thorac Oncol. 2021;16:1017-1029.
    PubMed     Abstract available


  311. FINN SP, Addeo A, Dafni U, Thunnissen E, et al
    Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.
    J Thorac Oncol. 2021;16:990-1002.
    PubMed     Abstract available


  312. STEUER CE, Jegede OA, Dahlberg SE, Wakelee HA, et al
    Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial.
    J Thorac Oncol. 2021;16:960-967.
    PubMed     Abstract available


    May 2021
  313. JAZIEH AR, Onal HC, Weng Tan DS, Soo RA, et al
    Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: Results of KINDLE, a multi-country observational study.
    J Thorac Oncol. 2021 May 26. pii: S1556-0864(21)02174.
    PubMed     Abstract available


  314. ZHOU C, Wu L, Fan Y, Wang Z, et al
    Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12).
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02128.
    PubMed     Abstract available


  315. HERBST RS, Garon EB, Kim DW, Cho BC, et al
    5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02172.
    PubMed     Abstract available


  316. JOHNSON AM, Boland JM, Wrobel J, Klezcko EK, et al
    Cancer cell-specific MHCII expression as a determinant of the immune infiltrate organization and function in the non-small cell lung cancer tumor microenvironment.
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02175.
    PubMed     Abstract available


  317. BARBI J, Patnaik SK, Pabla S, Zollo R, et al
    Visceral Obesity Promotes Lung Cancer Progression-Toward Resolution of the Obesity Paradox in Lung Cancer.
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02171.
    PubMed     Abstract available


  318. LU S, Wang J, Yu Y, Yu X, et al
    Tislelizumab Plus Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (RATIONALE 304): A Randomized Phase 3 Trial.
    J Thorac Oncol. 2021 May 22. pii: S1556-0864(21)02176.
    PubMed     Abstract available


  319. ZHAO H, Yao W, Min X, Gu K, et al
    Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706).
    J Thorac Oncol. 2021 May 22. pii: S1556-0864(21)02177.
    PubMed     Abstract available


  320. LOIOLA DE ALENCAR VT, Camandaroba MPG, Pirolli R, Fogassa CAZ, et al
    Immunotherapy as Single Treatment for Non-small-cell Lung Cancer Patients with Brain Metastases: a systematic review and meta-analysis - the META-L-BRAIN study.
    J Thorac Oncol. 2021 May 5. pii: S1556-0864(21)02131.
    PubMed     Abstract available


  321. OSAROGIAGBON RU, Ray MA, Faris NR, Smeltzer MP, et al
    Response to: "Lymph Node Dissection for Non-Small-Cell Lung Cancer at Whose Discretion?"
    J Thorac Oncol. 2021;16:e36-e37.
    PubMed    


  322. PIRKER R, Prosch H, Popper H, Klepetko W, et al
    Lung Cancer in Austria.
    J Thorac Oncol. 2021;16:725-733.
    PubMed    


  323. KIM CG, Cho BC, Lim SM
    Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?
    J Thorac Oncol. 2021;16:709-711.
    PubMed    


  324. LI M, Zhan C, Wang Q
    Is the Story of M Descriptors Fulfilled or Finished?
    J Thorac Oncol. 2021;16:e36-e37.
    PubMed    


  325. METOVIC J, Bianchi F, Barella M, Papotti M, et al
    SMARCA2 Deficiency While Preserving SMARCA4 and SMARCB1 in Lung Neuroendocrine Carcinomas.
    J Thorac Oncol. 2021;16:e32-e35.
    PubMed    


  326. DE CARLO E, Schiappacassi M, Del Conte A, Stanzione B, et al
    Combination of Chemotherapy and ALK Inhibitors in ALK-Positive NSCLC.
    J Thorac Oncol. 2021;16:e31-e32.
    PubMed    


  327. NISHIO M, Mendus D, Wang L, Socinski MA, et al
    Response to Letter to the Editor.
    J Thorac Oncol. 2021;16:e30-e31.
    PubMed    


  328. DI FEDERICO A, Nuvola G, Deiana C, Donati G, et al
    IMpower 132: Is the Second Exception to the Rule No Longer an Exception?
    J Thorac Oncol. 2021;16:e29-e30.
    PubMed    


  329. SEDOR G, Scott JG, Kattan MW, Torres-Roca JF, et al
    Letter Response.
    J Thorac Oncol. 2021;16:e28-e29.
    PubMed    


  330. MISTRY HB
    Simulating RTOG 0617 using Genomic Adjusted Radiation Dose: Comparing Apples With Oranges.
    J Thorac Oncol. 2021;16:e27.
    PubMed    


  331. RIMNER A, Wu AJ, Grills IS
    What Is the Impact of Hippocampus Avoidance-Prophylactic Cranial Irradiation on Neurocognitive Preservation?
    J Thorac Oncol. 2021;16:722-724.
    PubMed    


  332. WESTEEL V
    Surveillance After Curative-Intent Treatment for NSCLC: More to It Than Meets the Eye.
    J Thorac Oncol. 2021;16:719-721.
    PubMed    


  333. JULOORI A, Vokes EE
    Beyond PACIFIC: Uncharted Waters.
    J Thorac Oncol. 2021;16:715-718.
    PubMed    


  334. LIU SY, Wu YL
    Unmet Clinical Demand for Patients With Unresectable Stage III NSCLC Having Actionable Genetic Alterations.
    J Thorac Oncol. 2021;16:712-714.
    PubMed    


  335. ADJEI AA, Ignatius Ou SH, Ho C, Pujol JL, et al
    Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships.
    J Thorac Oncol. 2021;16:706-708.
    PubMed    


  336. MATSUI S, Le-Rademacher J, Mandrekar SJ
    Statistical Models in Clinical Studies.
    J Thorac Oncol. 2021;16:734-739.
    PubMed     Abstract available


  337. STIRLING RG, Chau C, Shareh A, Zalcberg J, et al
    Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2021;16:784-797.
    PubMed     Abstract available


  338. BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
    Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675).
    J Thorac Oncol. 2021;16:840-849.
    PubMed     Abstract available


  339. HELLYER JA, Aredo JV, Das M, Ramchandran K, et al
    Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.
    J Thorac Oncol. 2021;16:868-872.
    PubMed     Abstract available


  340. FAIVRE-FINN C, Vicente D, Kurata T, Planchard D, et al
    Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
    J Thorac Oncol. 2021;16:860-867.
    PubMed     Abstract available


  341. NAGASAKA M, Zhu VW, Lim SM, Greco M, et al
    Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.
    J Thorac Oncol. 2021;16:740-763.
    PubMed     Abstract available


  342. PASSARO A, Mok T, Peters S, Popat S, et al
    Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations.
    J Thorac Oncol. 2021;16:764-773.
    PubMed     Abstract available


    April 2021
  343. AI X, Pan Y, Shi J, Yang N, et al
    Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Extensive-Stage Small Cell Lung Cancer after First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02111.
    PubMed     Abstract available


  344. YONESHIMA Y, Morita S, Ando M, Nakamura A, et al
    Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non-small cell lung cancer.
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02107.
    PubMed     Abstract available


  345. HWANG DM, Albaqer T, Santiago RC, Weiss J, et al
    Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer.
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02108.
    PubMed     Abstract available


  346. QIAO M, Jiang T, Liu X, Mao S, et al
    Immune checkpoint inhibitors in EGFR-mutated non-small cell lung cancer: Dusk or Dawn?
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02113.
    PubMed     Abstract available


  347. ANDRUSKA N, Stowe HB, Crockett C, Liu W, et al
    Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios.
    J Thorac Oncol. 2021 Apr 23. pii: S1556-0864(21)02112.
    PubMed     Abstract available


  348. SAFIRI S, Sohrabi MR, Carson-Chahhoud K, Bettampadi D, et al
    Burden of tracheal, bronchus and lung cancer and its attributable risk factors in 204 countries and territories, 1990-2019.
    J Thorac Oncol. 2021 Apr 15. pii: S1556-0864(21)02110.
    PubMed     Abstract available


  349. PATAER A, Weissferdt A, Vaporciyan AA, Correa AM, et al
    Evaluation of Pathologic Response in Lymph Nodes of Lung Cancer Patients Receiving Neoadjuvant Chemotherapy.
    J Thorac Oncol. 2021 Apr 12. pii: S1556-0864(21)02109.
    PubMed     Abstract available


  350. BAUMEISTER SE, Baurecht H, Nolde M, Alayash Z, et al
    Cannabis use, pulmonary function, and lung cancer susceptibility: A Mendelian randomization study.
    J Thorac Oncol. 2021 Apr 11. pii: S1556-0864(21)02105.
    PubMed     Abstract available


  351. MEMMOTT RM, Wolfe AR, Carbone DP, Williams TM, et al
    Predictors of Response, Progression Free Survival, and Overall Survival in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
    J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)02072.
    PubMed     Abstract available


  352. PARK K, Ozguroglu M, Vansteenkiste J, Spigel D, et al
    Avelumab vs docetaxel in patients with platinum-treated advanced non-small-cell lung cancer: 2-year follow-up from the JAVELIN Lung 200 phase 3 trial.
    J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)01832.
    PubMed     Abstract available


  353. ALESSI JV, Ricciuti B, Spurr LF, Gupta H, et al
    SMARCA4 and other SWI/SNF family genomic alterations in non-small cell lung cancer: Clinicopathological characteristics and outcomes to immune checkpoint inhibition.
    J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)02104.
    PubMed     Abstract available


  354. LIU L, Bai H, Wang C, Seery S, et al
    Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02071.
    PubMed     Abstract available


  355. ODINTSOV I, Mattar MS, Lui AJW, Offin M, et al
    Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers.
    J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02068.
    PubMed     Abstract available


  356. THOMAS PL, Groves SM, Zhang YK, Li J, et al
    Beyond PD-L1: B7-H6 emerges as a potential immunotherapy target in small cell lung cancer.
    J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02066.
    PubMed     Abstract available


  357. JOHNSON ML, Zvirbule Z, Laktionov K, Helland A, et al
    Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study.
    J Thorac Oncol. 2021 Apr 3. pii: S1556-0864(21)02067.
    PubMed     Abstract available


  358. GOTO T
    Lymph Node Dissection for NSCLC at Whose Discretion?
    J Thorac Oncol. 2021;16:e25.
    PubMed    


  359. PAZ-ARES L
    Response to: Bintrafusp Alfa in Second-Line Treatment of Patients With NSCLC.
    J Thorac Oncol. 2021;16:e24.
    PubMed    


  360. XU J, Nie H, Wan H
    Bintrafusp Alfa in the Second-Line Treatment of Patients With NSCLC.
    J Thorac Oncol. 2021;16:e23-e24.
    PubMed    


  361. QIU H, Li Q, Xiao Y, Wu D, et al
    A Novel Intergenic Region Between KLHL31 and LRRC1-ALK Exon 20 Fusion Variant in Advanced Lung Adenocarcinoma and its Remarkable Response to ALK Inhibitor.
    J Thorac Oncol. 2021;16:e21-e23.
    PubMed    


  362. NAGASAKA M, Ou SI
    Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC.
    J Thorac Oncol. 2021;16:532-536.
    PubMed    


  363. CAMIDGE DR
    Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC.
    J Thorac Oncol. 2021;16:528-531.
    PubMed    


  364. GADGEEL SM
    Patient-Reported Outcomes in the Era of Immunotherapy Trials.
    J Thorac Oncol. 2021;16:516-518.
    PubMed    


  365. FALKSON CB
    Postoperative Radiation for Completely Resected Stage II/III Thymoma: What Do We Know in 2021?
    J Thorac Oncol. 2021;16:515.
    PubMed    


  366. PATEL SP, Kelly K
    IMpower 132: Loses Power at the Finish Line.
    J Thorac Oncol. 2021;16:512-514.
    PubMed    


  367. PACHECO JM, Schenk EL
    CD73 and Adenosine Receptor Signaling as a Potential Therapeutic Target in EGFR-Mutated NSCLC.
    J Thorac Oncol. 2021;16:509-511.
    PubMed    


  368. SEBASTIAN M, Stratmann JA, Eberhardt WEE
    Too Good to be True?
    J Thorac Oncol. 2021;16:507-508.
    PubMed    


  369. LE X
    Heterogeneity in MET-Aberrant NSCLC.
    J Thorac Oncol. 2021;16:504-506.
    PubMed    


  370. OU FS, Michiels S, Shyr Y, Adjei AA, et al
    Biomarker Discovery and Validation: Statistical Considerations.
    J Thorac Oncol. 2021;16:537-545.
    PubMed     Abstract available


  371. TATEISHI Y, Horita N, Namkoong H, Enomoto T, et al
    Postoperative Radiotherapy for Completely Resected Masaoka/Masaoka-Koga Stage II/III Thymoma Improves Overall Survival: An Updated Meta-Analysis of 4746 Patients.
    J Thorac Oncol. 2021;16:677-685.
    PubMed     Abstract available


  372. LE X, Negrao MV, Reuben A, Federico L, et al
    Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.
    J Thorac Oncol. 2021;16:583-600.
    PubMed     Abstract available


  373. LAM VK, Zhang J, Wu CC, Tran HT, et al
    Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC.
    J Thorac Oncol. 2021;16:601-609.
    PubMed     Abstract available


  374. VILLALBA JA, Shih AR, Sayo TMS, Kunitoki K, et al
    Accuracy and Reproducibility of Intraoperative Assessment on Tumor Spread Through Air Spaces in Stage 1 Lung Adenocarcinomas.
    J Thorac Oncol. 2021;16:619-629.
    PubMed     Abstract available


  375. MOONEN L, Derks JL, Hermans BCM, Bunnik IM, et al
    Preoperative Biopsy Diagnosis in Pulmonary Carcinoids, a Shot in the Dark.
    J Thorac Oncol. 2021;16:610-618.
    PubMed     Abstract available


    March 2021
  376. SCARFONE G, Fumagalli M, Imbimbo M, Ceruti T, et al
    First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report.
    J Thorac Oncol. 2021 Mar 29. pii: S1556-0864(21)01705.
    PubMed     Abstract available


  377. DY GK, Prasad D, Kumar P, Attwood K, et al
    A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy.
    J Thorac Oncol. 2021;16:e19-e20.
    PubMed    


  378. YANG X, Li Y, Duan Q, Zhang Q, et al
    Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment.
    J Thorac Oncol. 2021;16:e17-e19.
    PubMed    


  379. SHIELDS MD, Hicks JK, Boyle TA, Haura EB, et al
    Selpercatinib Overcomes CCDC6-RET-Mediated Resistance to Osimertinib.
    J Thorac Oncol. 2021;16:e15-e17.
    PubMed    


  380. UPRETY D
    Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting.
    J Thorac Oncol. 2021;16:371-374.
    PubMed    


  381. REMON J, Hendriks LEL
    Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:368-370.
    PubMed    


  382. ADJEI AA
    Controversies in Thoracic Oncology.
    J Thorac Oncol. 2021;16:366-367.
    PubMed    


  383. RAJAN A
    Immunotherapy for Thymic Cancers: A Convoluted Path Toward a Cherished Goal.
    J Thorac Oncol. 2021;16:352-354.
    PubMed    


  384. SONG L, Xu Q, Lizaso A, Zhang Y, et al
    Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC.
    J Thorac Oncol. 2021;16:349-351.
    PubMed    


  385. SONG Z, Lu C, Xu CW, Zheng Z, et al
    Noncanonical Gene Fusions Detected at the DNA Level Necessitate Orthogonal Diagnosis Methods Before Targeted Therapy.
    J Thorac Oncol. 2021;16:344-348.
    PubMed    


  386. WANG X, Piantadosi S, Le-Rademacher J, Mandrekar SJ, et al
    Statistical Considerations for Subgroup Analyses.
    J Thorac Oncol. 2021;16:375-380.
    PubMed    


  387. NILSSON MB, Robichaux J, Herynk MH, Cascone T, et al
    Altered Regulation of HIF-1alpha in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype.
    J Thorac Oncol. 2021;16:439-451.
    PubMed     Abstract available


  388. NG TL, Johnson A, Nemenoff RA, Hsieh E, et al
    Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation.
    J Thorac Oncol. 2021;16:486-491.
    PubMed     Abstract available


  389. LI W, Guo L, Liu Y, Dong L, et al
    Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
    J Thorac Oncol. 2021;16:404-418.
    PubMed     Abstract available


  390. GIACCONE G, Kim C
    Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up.
    J Thorac Oncol. 2021;16:483-485.
    PubMed     Abstract available


  391. SECHI E, Zekeridou A
    Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies.
    J Thorac Oncol. 2021;16:381-394.
    PubMed     Abstract available


    February 2021
  392. LEE J, Ahn MJ
    A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.
    J Thorac Oncol. 2021;16:e14.
    PubMed    


  393. ZHENG MM, Li YS, Sun H, Wu YL, et al
    Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.
    J Thorac Oncol. 2021;16:e12-e14.
    PubMed    


  394. TSUI DCC, Camidge DR
    Molecular Profiling of the Cerebrospinal Fluid in Leptomeningeal NSCLC: The Shape of Things to Come?
    J Thorac Oncol. 2021;16:194-196.
    PubMed    


  395. SEQUIST LV, Skates SJ, Haas W
    A New Era of Protein-Based Assays for Cancer Early Detection.
    J Thorac Oncol. 2021;16:191-193.
    PubMed    


  396. FERRARA R, Campochiaro C, Garassino MC
    Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events.
    J Thorac Oncol. 2021;16:183-186.
    PubMed    


  397. PADDA SK, Reckamp KL
    Combination of Immunotherapy and Antiangiogenic Therapy in Cancer-a Rational Approach.
    J Thorac Oncol. 2021;16:178-182.
    PubMed    


  398. MOK T, Peters S, Camidge DR, Noe J, et al
    Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.
    J Thorac Oncol. 2021;16:259-268.
    PubMed     Abstract available


  399. LI B, Zhang Y, Miao L, Ma L, et al
    Esophagectomy With Three-Field Versus Two-Field Lymphadenectomy for Middle and Lower Thoracic Esophageal Cancer: Long-Term Outcomes of a Randomized Clinical Trial.
    J Thorac Oncol. 2021;16:310-317.
    PubMed     Abstract available


  400. BANFILL K, Giuliani M, Aznar M, Franks K, et al
    Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions.
    J Thorac Oncol. 2021;16:216-227.
    PubMed     Abstract available


  401. GJYSHI O, Xu T, Elhammali A, Boyce-Fappiano D, et al
    Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC.
    J Thorac Oncol. 2021;16:269-277.
    PubMed     Abstract available


  402. PETERS S, Felip E, Dafni U, Tufman A, et al
    Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology P
    J Thorac Oncol. 2021;16:278-288.
    PubMed     Abstract available


  403. JIANG T, Fang Z, Tang S, Cheng R, et al
    Mutational Landscape and Evolutionary Pattern of Liver and Brain Metastasis in Lung Adenocarcinoma.
    J Thorac Oncol. 2021;16:237-249.
    PubMed     Abstract available


  404. OSTRIN EJ, Bantis LE, Wilson DO, Patel N, et al
    Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules.
    J Thorac Oncol. 2021;16:228-236.
    PubMed     Abstract available


  405. LE X, Nilsson M, Goldman J, Reck M, et al
    Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:205-215.
    PubMed     Abstract available


  406. MOI L, Bouchaab H, Mederos N, Nguyen-Ngoc T, et al
    Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis.
    J Thorac Oncol. 2021;16:318-326.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: